GlaxoSmithKline told that Avandia risks may be overstated
Glaxo said it found Avandia did not raise the risk of death, heart attack or stroke. Heath experts re-examining the company’s findings have now supported the conclusion. “We appreciate the committee’s thorough examination of the results and will continue to work with the FDA as it considers the recommendation of the committee,” Dr James Shannon, Glaxo’s chief medical officer, said in a statement last night. “We continue to believe that Avandia is a safe and effective treatment option for type…